#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Semaglutide safety in dialysis patients
A 2026 Diabetes Care exchange scrutinised pooled trial data on semaglutide safety after dialysis initiation. What the numbers show and what remains open.
Tirzepatide vs Semaglutide: Liver Risk
A large real-world study found tirzepatide and injectable semaglutide carry the same risk of serious liver outcomes in adults with type 2 diabetes.
Switching to Tirzepatide: Liver Fibrosis
A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.
Avexitide: the GLP-1 drug that blocks it
Avexitide, Amylyx's investigational GLP-1 receptor blocker, cut severe post-bariatric hypoglycemia events by 55 percent in a phase 3 trial.
GLP-1 Drugs and Ankle Osteoarthritis Care
A 2026 cohort study ties GLP-1 receptor agonist use to fewer ankle injections and replacements, but more arthroscopy in diabetes.
Semaglutide lowers hsCRP in SELECT
A Circulation analysis of SELECT finds semaglutide 2.4 mg reduces hsCRP in adults with prior heart attack or stroke. What it means, and what it doesn't.
Sleep and mood after starting GLP-1 drugs
A new observational study links tirzepatide and semaglutide to improved sleep and depression scores at three months, with caveats.
Doctor suspended over Ozempic to partner
A GMC tribunal suspended a UK doctor for prescribing Ozempic and Wegovy, both semaglutide, to her partner without disclosure.
Experts Issue GLP-1 Guidance for NET Care
A new expert consensus statement sets ground rules for using GLP-1 drugs like tirzepatide in neuroendocrine tumor patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
Ozempic in Pro-Eating-Disorder Communities
A 2026 study finds Ozempic, a semaglutide brand, is normalized more than warned against in a pro-eating-disorder community on X.
Semaglutide and aspiration risk in surgery
New ultrasound data and case reports on semaglutide, retained gastric content and aspiration are reshaping the pre-surgery cessation question.